Laurion Capital Management’s Blueprint Medicines BPMC Stock Holding History

Laurion Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-261,904	Closed	-$21M	–	913
2019 Q1	$21M	Buy	+261,904	New	+$19.4M	0.28%	71
2018 Q2	–	Sell	-6,400	Closed	-$587K	–	1339
2018 Q1	$587K	Sell	6,400 -66,562	-91%	-$5.74M	﹤0.01%	980
2017 Q4	$5.5M	Buy	72,962 +59,690	+450%	+$4.2M	0.03%	492
2017 Q3	$925K	Buy	+13,272	New	+$709K	﹤0.01%	1000
2017 Q2	–	Sell	-50,006	Closed	-$2M	–	1636
2017 Q1	$2M	Sell	50,006 -10,100	-17%	-$362K	0.02%	607
2016 Q4	$1.69M	Buy	+60,106	New	+$1.81M	0.02%	616

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Laurion Capital Management's BPMC Position: Q2 2019 in Review

Laurion Capital Management sold out of Blueprint Medicines (BPMC) in Q2 2019, closing a stake of 261,904 shares — an estimated $21M sold.

Laurion Capital Management first reported a position in BPMC in Q4 2016 and held it in 6 quarters. The position peaked at $21M in Q1 2019. 220 funds tracked by Wall St. Rank hold BPMC as of Q2 2019.

Laurion Capital Management reported no remaining Blueprint Medicines position as of Q2 2019 after selling out during the quarter.
Laurion Capital Management sold 261,904 Blueprint Medicines shares in Q2 2019, an estimated $21M.
Laurion Capital Management first reported a position in Blueprint Medicines in Q4 2016 and held it in 6 quarters.
Laurion Capital Management's Blueprint Medicines position peaked at $21M in Q1 2019.
220 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2019.

Based on Laurion Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.